Recombinant factor VIIa in orthotopic liver transplantation
- 1 February 2003
- journal article
- Published by Wolters Kluwer Health in Blood Coagulation & Fibrinolysis
- Vol. 14 (2) , 169-174
- https://doi.org/10.1097/00001721-200302000-00008
Abstract
The effect of recombinant factor VIIa (rFVIIa) on blood loss was evaluated in cirrhotic patients undergoing orthotopic liver transplantation. In the present study, we explored the effect of rFVIIa on coagulation and fibrinolysis during orthotopic liver transplantation. Coagulation factors, parameters of thrombin generation and parameters of fibrinolysis were measured in six patients who had received a single dose of 80 μg/kg rFVIIa and in ten controls, during and after orthotopic liver transplantation. Baseline concentrations and course of coagulation factors were similar in patients and controls. Thrombin generation did not rise after the administration of rFVIIa, but showed a sharp increase after reperfusion in patients, as compared with controls. No difference in fibrinolysis was apparent between patients and controls. No evidence of diffuse intravascular coagulation was seen. We conclude that the use of rFVIIa in orthotopic liver transplantation seems to enhance thrombin generation in a localized and time-limited matter, without causing systemic coagulation.Keywords
This publication has 16 references indexed in Scilit:
- REDUCED TRANSFUSION REQUIREMENTS BY RECOMBINANT FACTOR VIIa IN ORTHOTOPIC LIVER TRANSPLANTATIONTransplantation, 2001
- Blood loss in orthotopic liver transplantation: a retrospective analysis of transfusion requirements and the effects of autotransfusion of cell saver blood in 164 consecutive patientsBlood Coagulation & Fibrinolysis, 2000
- Vascular complications in a series of 300 orthotopic liver transplantsTransplantation Proceedings, 1999
- Sinusoidal endothelial cell injury during hepatic preservation and reperfusionHepatology, 1998
- Haemostatic system activation and prediction of vascular events in patients presenting with stable peripheral arterial disease of moderate severityBlood Coagulation & Fibrinolysis, 1998
- Platelet activity of high‐dose factor VIIa is independent of tissue factorBritish Journal of Haematology, 1997
- Pharmacokinetics and pharmacodynamics of recombinant factor VIIaClinical Pharmacology & Therapeutics, 1994
- Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa)Blood Coagulation & Fibrinolysis, 1993
- Mechanism by which recombinant factor VIIa shortens the aPTT: Activation of factor X in the absence of tissue factorThrombosis Research, 1989
- Hemostatic Evaluation of Patients Undergoing Liver TransplantationMayo Clinic Proceedings, 1987